Global Clinical Trials Fund

The Global Clinical Trials Fund supports clinical trials that have potential to be of benefit to dementia patients. Lead applicants and trial sites can be from the UK or international.

The remit of this scheme covers:

  • Studies that aim to demonstrate target engagement, Phase I or Phase II clinical trials undertaken to ascertain the potential safety and efficacy of (novel or re-purposed) drug-based interventions in human subjects
  • Clinical trials of non-drug based, complex interventions
  • Opportunities for research ‘add ons’ to ongoing clinical trials (e.g. validated biomarker add-ons).

This scheme is not designed to cover:

  • Interventions or devices for ‘assisted living’ or for care management
  • Observational/biomarker clinical studies – UK-based applications covering these are acceptable through Alzheimer’s Research UK’s other grant schemes (for which there must be a UK-based lead applicant). However, please note that validated biomarker studies can be included in an application to the Global Clinical Trials Fund as primary and/or secondary outcome measures of drug action or if considered as add-ons to ongoing clinical trials.

Duration: Dependent on proposal

Provides up to £1 million to cover salaries (research, technical, students etc), equipment, animal costs and running costs (consumables, travel etc).

Apply now

Application FAQs

  • Applications are accepted from lead applicants based at established academic/not-for-profit research institutions worldwide. The lead applicant is expected to have a contract with the host institution which covers the proposed duration of the project.
  • Applications must include at least one clinician and either a basic or clinical researcher.
  • Small and medium enterprises* are not permitted to apply as lead applicants but can be listed as co-applicants/collaborators on academic/not-for-profit-led projects.
  • Large commercial organisations may only participate as collaborators on academic/not-for-profit-led projects, in particular if these add value to the trial – for example, access to expertise, technologies, medical devices, drug supply or funding.

*We align with the European Commission’s current definitions of small and medium enterprises, which can be found here. Enterprises whose figures exceed those listed for a SME will generally be considered as large commercial organisations. If you wish to discuss your eligibility with us before applying, please contact us:

Download an Expression of Interest form. Please read the information in this section before applying or contact for more information.

An upper limit of £1,000,000 is set for each application as the total Alzheimer’s Research UK contribution. Applicants should be aware that they are competing for limited funds. Proposals should represent good value for money and all funding requests should be clearly justified.

Alzheimer’s Research UK covers any directly incurred costs within the terms of the award Contract. Payments of the grant are to be made quarterly in arrears following the receipt of authorised invoices.

Alzheimer’s Research UK is a National Institutes for Health Research non-commercial partner and therefore the Department of Health could meet some of the costs of non-commercial Alzheimer’s Research UK-funded research in the National Health Service. Please refer to the AcoRD guidelines for more information.

Alzheimer’s Research UK is flexible to different funding arrangements and applicants are encouraged to contact the Research Team ( early to discuss their projects and co-funding opportunities. Nevertheless, we envisage most applications to fall into one of the following categories:

  1.  Applications to Alzheimer’s Research UK to fully-fund a trial
  2.  Applications to Alzheimer’s Research UK to offer a financial commitment to be included in an application to another funder and that is dependent on an award by the other funder.
  3. Applications to Alzheimer’s Research UK to fund a trial jointly with other organisations.

GCTF diagram


Alzheimer’s Research UK is a member of the Association of Medical Research Charities and follows their guidelines for best practice in peer review. Grants are awarded on scientific merit in relation to Alzheimer’s Research UK’s remit and on the basis of open competition. The quality of the application and applicants are the key determinants of outcome, although the strength of the dementia research environment within the institution is also considered.

Expressions of Interest review

Our Clinical Trials Advisory Panel (CTAP) members are asked to read Expressions of Interest and recommend whether an application should proceed to the next stage of review.

Full application external review

Applications are subjected to external peer review. Applications are sent to researchers in the UK and worldwide who specialise in the area of the application, but who do not have a conflict of interest and are not a member of the CTAP. The comments made by the external reviewers are made available to the CTAP members.

Review response

The applicants are provided with anonymised copies of the external reviews and given the opportunity to provide a written response.

Lay review

Applications for research studies that involve people require lay review. Applicants are requested to complete a lay summary of their application which is sent to lay review volunteers for comments. The comments made by lay reviewers are made available to the CTAP members.

Discussion in meeting

Each application is allocated to two CTAP members, based roughly on their areas of expertise. The two members will present the application to the rest of the panel, including any relevant information from external reviews or applicant responses. A short discussion will follow before the CTAP score the application. Applications for each grant scheme are ranked by their average score and recommendations for funding are made.

Trustee meeting

Those applications recommended for funding by the CTAP are presented to the trustees for final approval.

The terms and conditions of grant differ for each grant scheme and contracts are drawn up individually once the grants have been awarded.


All grant holders are expected to report on the progress of their project on a regular basis. Read more about our reporting requirements on the measuring impact page.

For more information about any of the grant schemes or the application process please contact the Research Team or 0300 111 5555

Download our GDPR statement that explains how Alzheimer’s Research UK Research Team handles personal data about our grant applications and the rights that applicants have under data protection law. In this Notice, we refer to this type of information as “Applicant Data”.

This statement applies to applications submitted via Grant Tracker. It also applies to applications summitted via other means, such as by post and email.

Download GDPR statement

Up to £1,000,000

Supports Phase I and II clinical trials that have potential to be of benefit to people with dementia.

Key Dates

  • 14/11/2018
    Expression of Interest date. Feedback will be provided early February 2019
  • 08/05/2019
    Full application deadline, feedback will be provided
  • 17/04/2019
    Expression of Interest date. Feedback will be provided early July 2019
  • 02/10/2019
    Full application deadline, feedback will be provided Early February 2020